Table 3: Between-group analysis of different outcome measures at weeks 4, 8, and 12.

MeasuresOlanzapine
Risperidone
95% CI

SAPS-4th week61.44 ± 3.9261.23 ± 3.610.2160.82−1.74, 2.16
SAPS-8th week60.27 ± 3.8260.98 ± 3.58−0.7430.46−2.62, 1.20
SAPS-12th week54.96 ± 3.4256.31 ± 3.02−1.6210.11−3.02, 0.32
SANS-4th week45.19 ± 2.7345.69 ± 2.29−0.7690.44−1.80, 0.80
SANS-8th week44.91 ± 3.3745.76 ± 3.33−0.9830.32−2.58, 0.88
SANS-12th week42.74 ± 3.6945.28 ± 3.06−2.9020.005−4.29, −0.79
SAI-12th week 3.83 ± 0.113.97 ± 0.74−1.0250.30−0.41, 0.13
SAS-12th week0.38 ± 0.020.45 ± 0.19−2.0070.04−0.14, −0.00
CGI-S-12th week3.10 ± 1.033.17 ± 0.16−0.3680.71−0.45, 0.31

SAPS: Scale for Assessment of Positive Symptoms; SANS: Scale for Assessment of Negative Symptoms; CGI-S: Clinical Global Impressions-Severity Scale; SAI: Schedule for Assessment of Insight; SAS: Simpson Angus Scale.